Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.

ABSTRACT:

Introduction

In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not candidates for autologous stem cell therapy. Options may include palliative regimens or clinical trial enrollment. One therapy under investigation in diffuse large B-cell lymphoma is lenalidomide, an immunomodulatory agent with antiangiogenic activity.

Case presentation

We present the case of a 55-year-old Caucasian male patient diagnosed with diffuse large B-cell lymphoma who had an early relapse after treatment with rituximab, cyclopho

SUBMITTER: Krawczyk K 

PROVIDER: S-EPMC4191682 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature